A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Inclusion Criteria: * Age ≥80 years or frail ≥75 years, according to simplified comprehensive geriatric assessment * Histologically confirmed lymphoma belonging to one of the following subtypes: 1. diffuse large B-cell lymphoma, including transformation from an indolent lymphoma 2. follicular lymphoma grade 3B 3. T-cell/histiocyte-rich LBCL 4. primary cutaneous DLBCL, leg type 5. EBV-positive DLBCL, NOS 6. primary mediastinal LBCL 7. high grade B-cell lymphoma with MYC/BCL2 rearrangement * Stage II-IV disease * At least 1 measurable site of disease (\>1.5 cm long axis) * No previous treatment for lymphoma * WHO performance status 0 - 3 (Grade 3 if related to DLBCL) * Written informed consent Exclusion Criteria: * Severe cardiac disease: NYHA grade 3-4 * CNS involvement at diagnosis * Uncontrolled serious infection * Impaired liver (transaminases \> 3x normal upper limit or bilirubin \> 1.5 x normal upper limit, unless due to Gilbert´s syndrome) , renal (GFR\<30ml/min) or other organ function not caused by lymphoma, which will interfere with the treatment. * Absolute neutrophil count (ANC) \<1000 cells/µL or platelets \<100,000 cells/µL, unless due to lymphoma * Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma, unless treated with curative intent, and without relapse since 2 years, or low grade prostate cancer, not in need of treatment * Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study * Known hypersensitivity to rituximab, polatuzumab vedotin, cyclophosphamide, vincristine or doxorubicin, or HACA against rituximab * Peripheral neuropathy grade ≥ 2